CytomX Therapeutics, Inc. Operating Lease, Expense
CytomX Therapeutics, Inc. (CTMX) reported Operating Lease, Expense of $5.10 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2025-03-06
- CytomX Therapeutics, Inc. operating lease, expense for the quarter ending 2021-12-31 was $1.30M, a 0.00% change year-over-year.
- CytomX Therapeutics, Inc. operating lease, expense for the quarter ending 2021-09-30 was $1.30M, a 0.00% change year-over-year.
- CytomX Therapeutics, Inc. operating lease, expense for the quarter ending 2021-06-30 was $1.30M, a 0.00% change year-over-year.
- CytomX Therapeutics, Inc. operating lease, expense for the quarter ending 2021-03-31 was $1.30M, a 0.00% change year-over-year.
- CytomX Therapeutics, Inc. operating lease, expense for fiscal 2024 was $5.10M, a 0.00% change from fiscal 2023.
- CytomX Therapeutics, Inc. operating lease, expense for fiscal 2023 was $5.10M, a 0.00% change from fiscal 2022.
- CytomX Therapeutics, Inc. operating lease, expense for fiscal 2022 was $5.10M, a 0.00% change from fiscal 2021.
- CytomX Therapeutics, Inc. operating lease, expense for fiscal 2021 was $5.10M, a 0.00% change from fiscal 2020.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2024-12-31 | $5.10M 10-K · filed 2025-03-06 | |||
| 2023-12-31 | $5.10M 10-K · filed 2025-03-06 | |||
| 2022-12-31 | $5.10M 10-K · filed 2024-03-11 | |||
| 2021-12-31 | $1.30M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-27 | $2.60M derived: sum of 2 quarters · filed 2023-03-27 | $3.90M derived: sum of 3 quarters · filed 2023-03-27 | $5.10M 10-K/A · filed 2023-03-27 |
| 2021-09-30 | $1.30M 10-Q · filed 2021-11-04 | $2.60M derived: sum of 2 quarters · filed 2021-11-04 | $3.80M 10-Q · filed 2021-11-04 | $5.20M derived: sum of 4 quarters · filed 2023-03-27 |
| 2021-06-30 | $1.30M 10-Q · filed 2021-08-05 | $2.50M 10-Q · filed 2021-08-05 | $3.90M derived: sum of 3 quarters · filed 2023-03-27 | $5.20M derived: sum of 4 quarters · filed 2023-03-27 |
| 2021-03-31 | $1.30M 10-Q · filed 2021-05-06 | $2.60M derived: sum of 2 quarters · filed 2023-03-27 | $3.90M derived: sum of 3 quarters · filed 2023-03-27 | $5.20M derived: sum of 4 quarters · filed 2023-03-27 |
| 2020-12-31 | $1.30M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-27 | $2.60M derived: sum of 2 quarters · filed 2023-03-27 | $3.90M derived: sum of 3 quarters · filed 2023-03-27 | $5.10M 10-K/A · filed 2023-03-27 |
| 2020-09-30 | $1.30M 10-Q · filed 2021-11-04 | $2.60M derived: sum of 2 quarters · filed 2021-11-04 | $3.80M 10-Q · filed 2021-11-04 | $4.90M derived: sum of 4 quarters · filed 2023-03-27 |
| 2020-06-30 | $1.30M 10-Q · filed 2021-08-05 | $2.50M 10-Q · filed 2021-08-05 | $3.60M derived: sum of 3 quarters · filed 2023-03-27 | $4.90M derived: sum of 4 quarters · filed 2023-03-27 |
| 2020-03-31 | $1.30M 10-Q · filed 2021-05-06 | $2.30M derived: sum of 2 quarters · filed 2023-03-27 | $3.60M derived: sum of 3 quarters · filed 2023-03-27 | $4.90M derived: sum of 4 quarters · filed 2023-03-27 |
| 2019-12-31 | $1.00M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-27 | $2.30M derived: sum of 2 quarters · filed 2023-03-27 | $3.60M derived: sum of 3 quarters · filed 2023-03-27 | $4.80M 10-K/A · filed 2023-03-27 |
| 2019-09-30 | $1.30M 10-Q · filed 2020-11-05 | $2.60M derived: sum of 2 quarters · filed 2020-11-05 | $3.80M 10-Q · filed 2020-11-05 | $4.30M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-06-30 | $1.30M 10-Q · filed 2020-08-06 | $2.50M 10-Q · filed 2020-08-06 | $3.00M derived: sum of 3 quarters · filed 2021-02-24 | $4.30M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-03-31 | $1.30M 10-Q · filed 2020-05-07 | $1.70M derived: sum of 2 quarters · filed 2021-02-24 | $3.00M derived: sum of 3 quarters · filed 2021-02-24 | $4.30M derived: sum of 4 quarters · filed 2021-02-24 |
| 2018-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $1.70M derived: sum of 2 quarters · filed 2021-02-24 | $3.00M derived: sum of 3 quarters · filed 2021-02-24 | $4.20M 10-K · filed 2021-02-24 |
| 2018-09-30 | $1.30M 10-Q · filed 2019-11-07 | $2.60M derived: sum of 2 quarters · filed 2019-11-07 | $3.80M 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $1.30M 10-Q · filed 2019-08-07 | $2.50M 10-Q · filed 2019-08-07 | ||
| 2018-03-31 | $1.30M 10-Q · filed 2019-05-09 | |||
| 2017-12-31 | $4.20M 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |